Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Dry Eye Disease (DED) Clinical Trial

Official title:
A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Status Completed

Clinical Trial Summary

This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04139798
Study type	Interventional
Source	Bausch & Lomb Incorporated
Contact
Status	Completed
Phase	Phase 3
Start date	July 20, 2020
Completion date	March 12, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04140227` - Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)	Phase 3
Completed	`NCT04393441` - Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease	Phase 3
Completed	`NCT04036292` - Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease	Phase 3
Completed	`NCT04523142` - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004	Phase 3
Completed	`NCT03333057` - Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)	Phase 2
Completed	`NCT01998802` - Phase 3 Study of EBI-005 in Dry Eye Disease	Phase 3
Completed	`NCT05723770` - Effects of NOV03 on the Tear Film	Phase 4